Abraham Ceesay - 15 Aug 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role
President
Signature
/s/ Scott Akamine, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Aug 2022
Net transactions value
-$201,246
Form type
4
Filing time
17 Aug 2022, 16:15:13 UTC
Previous filing
09 Aug 2022
Next filing
24 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $126,511 +9,606 $13.17 9,606 15 Aug 2022 Direct F1
transaction CERE Common Stock Sale $327,757 -9,606 -100% $34.12 0 15 Aug 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -9,606 -2.4% $0.000000 393,824 15 Aug 2022 Common Stock 9,606 $13.17 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person.
F2 25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.